Leaders in Pharmaceutical Business Intelligence (LPBI) Group

LPBI Update

Curator: Gail S. Thornton, MA, PhD(c)

 

 

 

Newsletter #1 – February 2020

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Reporter: Gail S. Thornton, M.A.

 

Welcome to the premier issue of LPBI Group News, where readers can find relevant news and updates about science, business and medical innovation. This newsletter is distributed as a service for our readers.

• The Conference Forum Highlights Immuno-Oncology 360° in New York

The Conference Forum is hosting Immuno-Oncology 360°, which reports on current data and developments of immuno-oncology in the science and business communities. The summit takes place on February 26-28 at the Crowne Plaza Times Square in New York.

Please visit www.io360summit.com to register and use code LPBI20 for a 20% discount.

 

 

Ahead of the conference, Immuno-Oncology 360° has created a series celebrating their women speakers in the work they are doing to fight cancer. To read the series, visit: https://theconferenceforum.org/conferences/immuno-oncology-360/io360%cb%9a-leadership-interviews/

This information is published in conjunction with the Immuno-Oncology 360° Summit.

 

•  Venture Summit Attracts Top Innovators in Silicon Valley

Leaders in Pharmaceutical Business Intelligence (LPBI) Group is one of the sponsors of Venture Summit | West, “Where Innovation Meets Capital.”

The meeting will be held on March 23-24 at the Santa Clara Convention Center, Silicon Valley.

Special offer:  Register Now & Save $450 off (Use discount code “LPBI-VIP”)

For more information, please visit: https://pharmaceuticalintelligence.com/2019/12/17/venture-summit-west-where-innovation-meets-capital-march-23rd-24th-2020-santa-clara-convention-center-silicon-valley/

•  e-Proceedings of 15th Annual Personalized Medicine Conference at Harvard Medical School

The 15^th Annual Personalized Medicine Conference at Harvard Medical School, Boston last year [November 13-14, 2019], entitled  The Paradigm Evolves, explored the science, business and policy issues facing personalized medicine. In today’s world, scientists need to understand how molecular diagnostics augmented by artificial intelligence, data analytics and digital health empowers physicians and patients in their health care decisions.

Please visit for LPBI Group coverage of the meeting, including social media activities at the conference:

https://pharmaceuticalintelligence.com/2019/07/19/15th-annual-personalized-medicine-conference-at-harvard-medical-school-the-paradigm-evolves-november-13-14-2019-%e2%80%a2-harvard-medical-school-boston-ma/

https://pharmaceuticalintelligence.com/2019/11/15/tweets-and-retweets-by-aviva1950-and-by-pharma_bi-for-15th-annual-personalized-medicine-conference-at-harvard-medical-school-the-paradigm-evolves-november-13-14-2019-%e2%80%a2/

 

•  3D Medical BioPrinting Technology Featured in Podcast

LPBI Group leaders, Aviva Lev-Ari, Ph.D., R.N., Stephen Williams, Ph.D., and Irina Robu, Ph.D., spoke with Partners in Health and Biz, a half-hour audio podcast that reaches 40,000 listeners, about the topic of 3D Medical BioPrinting Technology: A Revolution in Medicine.

Please click on this link to hear the podcast. https://www.youtube.com/watch?v=laozyrfi29c.

The topic is also the title of a recently offered e-book by the LPBI Group on 3D BioPrinting, available on Amazon/Kindle Direct [https://www.amazon.com/Medical-BioPrinting-Technologies-Patient-centered-Patient-Centered-ebook/dp/B078QVDV2W].

The 3D BioPrinting technology is being used to develop advanced medical practices that will help with previously difficult processes, such as delivering drugs via micro-robots, targeting specific cancer cells and even assisting in difficult eye operations.

The table of contents in this book includes: Chapter 1: 3D Bioprinting: Latest Innovations in a Forty year-old Technology. Chapter 2: LPBI Initiative on 3D BioPrinting, Chapter 3: Cardiovascular BioPrinting, Chapter 4: Medical and Surgical Repairs – Advances in R&D Research, Chapter 5: Organ on a Chip, Chapter 6: FDA Regulatory Technology Issues, Chapter 7: DNA Origami, Chapter 8: Aptamers and 3D Scaffold Binding, Chapter 9: Advances and Future Prospects, Chapter 10: BioInks and MEMS, Chapter 11: BioMedical MEMS, Chapter 12: 3D Solid Organ Printing and Chapter 13: Medical 3D Printing: Sources and Trade Groups – List of Secondary Material.

 

• New e-Book: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

  LPBI Group’s latest e-book entitled, Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology, offers the reader content curation with embedded videos and audio podcasts, real-time conference e-Proceedings by LPBI’s scientists and professors and archived tweets of quotes from speakers at leading biotechnology conferences.

  Please click on this link on Amazon/Kindle Direct: https://www.amazon.com/dp/B08385KF87

 

The book integrates in a single volume four distinct perspectives: basic science, technologies and methodologies, clinical aspects and business and legal aspects of genomics research. “The materials in this book represents the scientific frontier in Biological Sciences and Medicine related to the genomics aspects of disease onset,” said Aviva Lev-Ari, Ph.D., R.N., and founder of LPBI Group.

The book addresses:

• aspects of life: the Cell, the Organ, the Human Body and Human Populations;
• methodologies of genomic data analysis: Next Generation Sequencing, Gene Editing, AI, Single Cell Genomics, Evolution Biology Genomics, Simulation Modeling in Genomics, Genotypes and Phenotypes Modeling, measurement of Epigenomics effects on disease, and developments in Pharmaco-Genomics.

Additionally, artificial Intelligence in medicine is covered in Part 3 of the e-Book, which represents the frontier in this emerging field, with topics, such as the science, technologies and methodologies, clinical aspects, business and legal implications as well as the latest machine learning algorithms harnessed for medical diagnosis.

This e-book is significant because it:

• contains 326 articles on topics, such as gene editing, bioinformatics and genome ontology;
• incorporates 74 e-Proceedings created in real time by the Book’s authors and editors
• includes four collections of Tweets representing quotes from speakers at global leading conferences on Genomics
• has 13 locations of Videos and Audio Podcasts that serve to enrich the e-Reader’s experience.

We welcome your comments and suggestions. Please send them to Aviva Lev-Ari at avivalev-ari@alum.berkeley.edu.

 

DRAFT –

Newsletter #2 – March 2020

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

 

March 2020 Newsletter:

LPBI Group’s VAST intellectual property (IP) portfolio defined to include:

• Three asset classes of TEXT: A, B, C
• One asset class of Interoperable Cloud-based IT infrastructure & applications: D
• One asset class of graphic images [non-text]: E
• One asset class of human resources: F

1.  LPBI Scientific Journal:

https://lnkd.in/eEw5q7N

1.7Million eReaders, 5700 scientific articles, 690 categories of research

1.  BioMed e-Series:

https://lnkd.in/ekWGNqA

16 Volumes in Medicine

1.  e-Proceedings:

https://lnkd.in/dc2qGAK

Corpus of 70 events covered in real time

1.  Platform, systems and composition of methods in addition to above three universes of deep content. 
2.  Journal’s ART GALLERY – collection of biological images courtesy of Google Images and Shutterfly placed in original collages and inside articles for used ORIGINAL to EAWs on LPBI Group’s Team
3.   The Team

LPBI Group’s PLAN for Global Projects Post Completion of BioMed e-Series and during transition to Transfer of Ownership

• France – active relations with the equivalent of AMA for Journal subscription

Aviva’s Contact: JS

• Spain – Dean of Madrid School of Medicine – on consideration e-Books for Medical Education

Aviva’s Contact: Dr. AF

• Russia – ongoing Translation Project of all 16 e-Books to Russian

Aviva’s Contact: George

• LATIN AMERICA

Aviva’s Contact: Marina Jancso

• Japan – Asian largest Conference organizer in Medicine to use our e-Proceeding archive to plan Conference in 2021

Aviva’s Contact: SP

• England – same as Japan

Aviva’s contact: DN

• Germany – Contract with distributor to sale e-Books in Soft cover in Germany

Aviva’s Contact: Dr. BjornB

• Israel – AI in Pharma algorithms are applied to our 5,700 for drug repurposing and for alternative therapeutics for the most expensive indication a Payor covers at present insurance policy

Aviva’s Contact: Ofer Markman

• France – Lyon’s Biotech Hub gets access to LPBI IP for drug discovery research

Aviva’s Contact: Dr. BinahB

• US – 2020 Pipeline Plans as in

https://pharmaceuticalintelligence.com/audio-podcasts/

 

#3

Old Industrial Revolution Paradigm of Education Needs to End: How Scientific Curation Can Transform Education

Curator: Stephen J. Williams, PhD.

https://pharmaceuticalintelligence.com/2020/01/05/old-industrial-revolution-paradigm-of-education-needs-to-end-how-scientific-curation-can-transform-education/

#4

Discussion on Open Access to Scientific knowledge

The REFERENCES to this article published in this Open Access Online Scientific Journal curated by Aviva and Dr. Williams

• eScientific Publishing a Case in Point: Evolution of Platform Architecture Methodologies and of Intellectual Property Development (Content Creation by Curation) Business Model
• Analysis of Utilizing LPBI Group’s Scientific Curation Platform as an Educational Tool: New Paradigm for Student Engagement
• Curation Methodology – Digital Communication Technology to mitigate Published Information Explosion and Obsolescence in Medicine and Life Sciences
• Democratizing Data Science Education (Video)
• e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point
• Innovations in electronic Scientific Publishing (eSP): Case Studies in Marketing eContent, Curation Methodology, Categories of Research Functions, Interdisciplinary conceptual innovations by Cross Section of Categories, Exposure to Frontiers of Science by Real Time Press coverage of Scientific Conferences

are about CURATIONS of Scientific basic research findings and clinical interpretation by EXPERTS

—>> Such curations are what LPBI Group created since 4/2012

—>> Such curations the value we bring to a potential acquirer in the LifeSciences, Medicine, pharmaceutical domain.

—>> we did it in three channels for knowledge dissemination OF OUR COLLABORATIVE formulations:

1. One Article Format of Curation by Experts was replicated by collaborations with other team members >5,700 TIMES
2. Expert Editors created electronic Table of Contents (eTOCs) for our 1st e-Book published 6/2013. We REPLICATED the process on eTOCs creation by Expert Editors SIXTEEN TIMES, 12/28/2019, last volume placed on the Medicine & Life Sciences in Kindle Store – our Genomics Volume 2 on AI in Medicine
3. 4/2013 was first BioIT Aviva covered in real time and created the first e-Proceedings, Dr. Williams created Twitter Analytics for it, WE IMPROVED AND REPLICATED this process >70 TIMES

These three CORPUSES are seeking Transfer of Ownership and monetization in 2020.

Three Scenarios on HOW TO POSITION LPBI Group for 2020 and Beyond:

Scenario 1:

We are what we are:

1.1 Journal – 5700 scientific articles:

1400 are LHB’s

1000 are All Scientists combined

3355 are ALA’s

1.2 BioMed e-Series – average length of book: 2400 pages, Sixteen Volumes in five specialties of Medicine

– Cardiovascular – 6 volumes

– Genomics – 2 volumes

– Cancer – 2 volumes

– Immune System & Infectious Diseases – 3 volumes

– Precision Medicine – 4 volumes

1.3 Seventy eProceedings and Collections of Tweets made in Real time at 70 most prominent Biotech & Medicine Global Conferences, 2013-2020

1.4 Platform, composition of methods, workflow, templates to produce 1.1, 1.2, 1,3, above – The tools 🛠 🧰 to create curations for Journals and Books 

1.5 A collection of 5,000 graphics of biological images used in 1.4

1.6 The Team

Scenario #2:

Scenario #1 plus NLP-AI derived insights

Scenario #3:

Only insights derived from the application of NLP-AI on our three CORPUSES

1.1 apply on every article,

N = 5700

1.2 apply on every eBook,

N = 16

1.3 apply on every eProceedings N = 70 and on every collection of Tweets N = 30

What is the BEST POSITIONING FOR EXIT:

Scenario #1: we are what we are

Scenario #2: Application of NLP-AI on Scenario #1

Scenario #3: Only the outcome of Scenario #2 targeted to problem solving in 12 economic segment of the economy